Literature DB >> 15335456

Parity confers better prognosis in older women with early-stage breast cancer treated with breast-conserving therapy.

Penny R Anderson1, Alexandra L Hanlon, Gary M Freedman, Nicos Nicolaou.   

Abstract

A comparison was made of pretreatment characteristics and outcomes of patients with stage I/II breast cancer treated with breast-conserving therapy who had a history of parity with those who were nulliparous. From 1979 to 1996, 1358 women with stage I/II (T1/2 N0/1 M0) breast cancer underwent lumpectomy, axillary dissection, and radiation therapy with or without systemic therapy. Of the total population, 1162 patients (86%) were parous and 196 patients (14%) were nulliparous. The median follow-up was 87 months. The 2 groups were compared for clinical, pathologic, and treatment-related factors. Multivariate analysis was used to determine independent predictors of outcome. Outcome was also evaluated for patterns of failure including distant metastases (DM), cause-specific survival (CSS), and overall survival (OS). Significant differences between the 2 groups were observed for age > 60 years and median age. Multivariate analysis demonstrated that nulliparous status was an independent predictor of DM, CSS, and OS after adjusting for age. Multivariate analysis for DM, CSS, and OS for patients > 60 years of age demonstrated that parity was the most highly significant independent predictor of decreased DM and improved OS. Parity can be considered a prognostic factor in elderly patients with early-stage breast cancer, and therefore may be used as a tool for identifying patients who may benefit from a more aggressive treatment approach.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15335456     DOI: 10.3816/cbc.2004.n.026

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  4 in total

1.  Reproductive factors and histologic subtype in relation to mortality after a breast cancer diagnosis.

Authors:  S Warren Andersen; P A Newcomb; J M Hampton; L Titus-Ernstoff; K M Egan; A Trentham-Dietz
Journal:  Breast Cancer Res Treat       Date:  2011-07-19       Impact factor: 4.872

2.  Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry.

Authors:  Kelly-Anne Phillips; Roger L Milne; Dee W West; Pamela J Goodwin; Graham G Giles; Ellen T Chang; Jane C Figueiredo; Michael L Friedlander; Theresa H M Keegan; Gord Glendon; Carmel Apicella; Frances P O'Malley; Melissa C Southey; Irene L Andrulis; Esther M John; John L Hopper
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

3.  Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype.

Authors:  Xuezheng Sun; Hazel B Nichols; Chiu-Kit Tse; Mary B Bell; Whitney R Robinson; Mark E Sherman; Andrew F Olshan; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-06       Impact factor: 4.254

4.  Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium.

Authors:  Anna Morra; Audrey Y Jung; Marjanka K Schmidt; Jenny Chang-Claude; Sabine Behrens; Renske Keeman; Thomas U Ahearn; Hoda Anton-Culver; Volker Arndt; Annelie Augustinsson; Päivi K Auvinen; Laura E Beane Freeman; Heiko Becher; Matthias W Beckmann; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Hermann Brenner; Ignacio Briceno; Sara Y Brucker; Nicola J Camp; Daniele Campa; Federico Canzian; Jose E Castelao; Stephen J Chanock; Ji-Yeob Choi; Christine L Clarke; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Thilo Dörk; Alison M Dunning; Miriam Dwek; Douglas F Easton; Diana M Eccles; Kathleen M Egan; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Susan M Gapstur; José A García-Sáenz; Mia M Gaudet; Graham G Giles; Mervi Grip; Pascal Guénel; Christopher A Haiman; Niclas Håkansson; Per Hall; Ute Hamann; Sileny N Han; Steven N Hart; Mikael Hartman; Jane S Heyworth; Reiner Hoppe; John L Hopper; David J Hunter; Hidemi Ito; Agnes Jager; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Rudolf Kaaks; Daehee Kang; Pooja Middha Kapoor; Cari M Kitahara; Stella Koutros; Peter Kraft; Vessela N Kristensen; James V Lacey; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Michael Lush; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Shivaani Mariapun; Keitaro Matsuo; Dimitrios Mavroudis; Roger L Milne; Taru A Muranen; William G Newman; Dong-Young Noh; Børge G Nordestgaard; Nadia Obi; Andrew F Olshan; Håkan Olsson; Tjoung-Won Park-Simon; Christos Petridis; Paul D P Pharoah; Dijana Plaseska-Karanfilska; Nadege Presneau; Muhammad U Rashid; Gad Rennert; Hedy S Rennert; Valerie Rhenius; Atocha Romero; Emmanouil Saloustros; Elinor J Sawyer; Andreas Schneeweiss; Lukas Schwentner; Christopher Scott; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Melissa C Southey; Daniel O Stram; Rulla M Tamimi; William Tapper; Rob A E M Tollenaar; Ian Tomlinson; Diana Torres; Melissa A Troester; Thérèse Truong; Celine M Vachon; Qin Wang; Sophia S Wang; Justin A Williams; Robert Winqvist; Alicja Wolk; Anna H Wu; Keun-Young Yoo; Jyh-Cherng Yu; Wei Zheng; Argyrios Ziogas; Xiaohong R Yang; A Heather Eliassen; Michelle D Holmes; Montserrat García-Closas; Soo Hwang Teo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-01-26       Impact factor: 4.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.